vida: extract claims from 2026-04-24-annals-im-semaglutide-tobacco-use-disorder-real-world

- Source: inbox/queue/2026-04-24-annals-im-semaglutide-tobacco-use-disorder-real-world.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -10,17 +10,10 @@ agent: vida
 sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md
 scope: causal
 sourcer: PubMed/ClinicalTrials.gov systematic review
-challenges:
+challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement"]
-related:
+supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery"]
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
+reweave_edges: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24"]
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-supports:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
-- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
-reweave_edges:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24
-- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24
 ---
 
 # GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
@@ -33,3 +26,9 @@ A systematic review of ClinicalTrials.gov identified 33 registered trials examin
 **Source:** Zhu et al., Science 2025, Vol. 387, eadt0773
 
 The same VTA dopamine circuit identified for hedonic eating (periLC → VTA_DA → NAc) is the mesolimbic dopamine pathway implicated in addiction. The study shows GLP-1Rs suppress VTADA neuron responsiveness during consumption, providing the specific circuit mechanism for GLP-1's effects on substance use disorders. The tolerance finding (circuit adaptation during repeated treatment) may also explain variable efficacy in addiction trials.
+
+## Extending Evidence
+
+**Source:** Annals of Internal Medicine 2024, target trial emulation + exenatide RCT
+
+Target trial emulation (real-world data) shows semaglutide associated with significantly lower risk of medical encounters for tobacco use disorder diagnosis compared with other antidiabetes medications, with strongest effect vs. insulins. Phase 2 RCT (exenatide + NRT) showed increased smoking abstinence vs. placebo + NRT, with reduced cravings and withdrawal symptoms. However, dulaglutide + varenicline RCT showed null result, likely due to ceiling effect (adding GLP-1 to already-effective varenicline). Mechanism consistent with VTA dopamine pathway modulation. This extends the reward circuit claim to a third substance type (tobacco), though evidence is mixed compared to AUD and obesity.

inbox/archive/health/2026-04-24-annals-im-semaglutide-tobacco-use-disorder-real-world.md

@@ -7,9 +7,12 @@ date: 2024
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-24
 priority: low
 tags: [glp-1, semaglutide, smoking, tobacco, nicotine, addiction, real-world-data, reward-circuit, VTA-dopamine]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content